* Option results in $21.9M payment from U.S. Government KVISTGAARD, Denmark, April 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised an option at a value of USD 21.9 million under the existing development contract for freeze-dried IMVAMUNE smallpox vaccine. This will fund the transfer of the already validated manufacturing process to a commercial manufacturing line with a larger capacity. Under the freeze-dried contract, which was awarded in 2009, the Company has validated the freeze-dried manufacturing process and shown the freeze-dried formulation to induce an equivalent immune response and efficacy as the current liquid frozen formulation in numerous animal models. The execution of this option follows the completion of enrollment of 680 healthy subjects in a Phase 2 study designed to meet the clinical requirements for emergency use in the U.S. of the freeze-dried formulation of the vaccine, which would enable the product to be stockpiled. A freeze-dried formulation is expected to reduce life cycle management costs based on a longer shelf life. Data from the study are expected to be submitted to the FDA in 2015, potentially supporting the production and supply of freeze-dried IMVAMUNE in 2016. Procurement would need to be conducted through a new contract, which the Company expects to initiate dialogue with the U.S. Government in 2014. The exercise of the option does not change the Company's financial guidance for 2014. Asger Aamund Chairman of the Board Contacts Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. [HUG#1778500]
Bavarian Nordic Announces Execution of Option on
Top 10 Most Recent News Articles
Amplifon Data Breach Spurs Legal Scrutiny for Millions
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
Novo's Semaglutide Shows Promise in MASH Study
Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...
Continue Reading
Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt
An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...
Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth
AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...
Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth
Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...
Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings
The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...
Continue Reading
PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech
CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...
Continue Reading
AWS Boosts Agilix's AI Education in Sierra Leone
Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...
Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps
In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...
Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue ReadingTop 5 Most Recently Viewed Articles
EssilorLuxottica Reports Share Capital and Voting Rights Update
Overview of EssilorLuxottica's Share Capital EssilorLuxottica, a prominent global leader in eyewear design, manufacture, and distribution, provides a detailed disclosure of its outstanding share capital and voting rights as of a recent date. This information is essential for shareholders and market watchers to understand the company's governance and share structure. Share...
Continue Reading
WM Technology, Inc. Faces Class Action Lawsuit with SEC Fallout
WM Technology, Inc. Faces Legal Challenges Recently, a class action lawsuit has arisen against WM Technology, Inc. (NASDAQ: MAPS), a pivotal player in the online cannabis marketplace. The Pomerantz Law Firm has initiated this legal action on behalf of affected investors. As the case unfolds, individuals who believe they have been impacted by the company's actions are...
Continue Reading
EVgo Targets 2026 for Profitable Future Amid Challenges
EVgo Overview EVgo Inc. (NASDAQ: EVGO) has faced recent fluctuations in share price following the announcement of its fiscal third-quarter results. The company operates one of the largest public electric vehicle charging networks in the United States, and it has been navigating a challenging landscape in the EV sector. Financial Performance Analysis In its latest report,...
Continue Reading
CNX Resources Corporation Reveals Financial Updates and Call Schedule
CNX Resources Corporation Financial Results Announcement CNX Resources Corporation (NYSE: CNX) is set to unveil its financial results for the fourth quarter of 2025. This important event will take place at 6:45 a.m. Eastern Time on an upcoming Thursday. During this announcement, CNX intends to release a concise press statement that will include essential documents linking...
Continue Reading
Nvidia's Revolutionary AI Dominance and Future Outlook
Understanding AI and Nvidia's Impact Since the dawn of the internet, investors have seen many trends come and go, but few have been as impactful as the artificial intelligence (AI) revolution. This groundbreaking technology has sparked interest among both seasoned professionals and everyday investors, all eager to explore its immense potential. It’s estimated that AI...
Continue Reading